Get started
Author

Bin Wang

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2024 · Anna E. Maciag, James P. Stice, et al. · Cancer Discovery · 71
Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin
2008 · Wenxue Zhao, Qianqian Han, et al. · Journal of Molecular Medicine · 46
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
2025 · Dhirendra K. Simanshu, Rui Xu, et al. · Science · 40
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al. · Cancer Discovery · 12
Urinary Retention, Incontinence, and Dysregulation of Muscarinic Receptors in Male Mice Lacking Mras
2015 · Annette Ehrhardt, Bin Wang, et al. · PLoS ONE · 10
PDF
Supplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S5 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Supplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S5 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Suppl. Materials and Methods 1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S7 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Supplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S6 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Supplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S8 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Table S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S3 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Supplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026 · Carlos Stahlhut, Anna E. Maciag, et al.
Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2026 · Anna E. Maciag, James P. Stice, et al.
Data from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2025 · Anna E. Maciag, James P. Stice, et al.
Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
2025 · Anna E. Maciag, James P. Stice, et al.
Works count: 33
Citation count: 179
H-index: 5
I10-index: 5
Year
Topic
Type